Baseline characteristics of study population

Slides:

Advertisements

Similar presentations

Sibbing D, et al. J Am Coll Cardiol 2009;53:

Advertisements

Trial profile Fox K et al. Lancet 2008;372:

Slide Source: Lipids Online Slide Library Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT): Design Cannon CP.

TNT: Study Design Treating to New Targets 2 5 years 10,001 Patients Clinically evident CHD LDL-C 130  250 mg/dL following up to 8-week washout and 8-week.

VBWG HPS. Lancet. 2003;361: Gæde P et al. N Engl J Med. 2003;348: Recent statin trials: Reduction in primary outcome in patients with diabetes.

VBWG BRAVER Trial BRachial Artery Vascular Endothelium Reactivity Study A substudy of PROVE IT-TIMI 22.

ALLHAT 6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (3 GROUPS by GFR)

Bangalore S, et al. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012;308(13): ?

6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (4 GROUPS by GFR) ALLHAT.

Ischemia Management with Accupril Post Bypass Graft via Inhibition of Angiotensin Converting Enzyme IMAGINEIMAGINE Presented at The European Society of.

Date of download: 6/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Early and long-term clinical outcomes associated.

The JUPITER Trial Reference Ridker PM. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.

Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Fractional Flow Reserve Versus Angiography for Guiding.

Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Making Sense of Statistics in Clinical Trial Reports:

Date of download: 7/10/2016 Copyright © The American College of Cardiology. All rights reserved. From: Risk of Stroke With Coronary Artery Bypass Graft.

Date of download: 9/16/2016 Copyright © The American College of Cardiology. All rights reserved. From: 5-Year Clinical Outcomes of the ARTS II (Arterial.

From: Bivalirudin Versus Heparin With or Without Glycoprotein IIb/IIIa Inhibitors in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention:

Impact of Triglyceride Levels Beyond Low-Density Lipoprotein Cholesterol After Acute Coronary Syndrome in the PROVE IT-TIMI 22 Trial Michael Miller MD,

Trial profile SAS denotes the Simvastatin in Aortic Stenosis Study

HOPE: Heart Outcomes Prevention Evaluation study

Clinical need for determination of vulnerable plaques

Extension of survival in months for various subgroups of patients with chronic stable angina treated by surgery as compared with those treated by medicine.

Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment:

Acute Kidney Injury and In-Hospital Mortality after Coronary Artery Bypass Graft versus Percutaneous Coronary Intervention: A Nationwide Study Shen et.

PAD Patients vs Post-ACS Patients:

Eugene Braunwald, MD, Marc S. Sabatine, MD, MPH

Figure 2 Imaging of atherosclerotic plaque burden

SMILE Trial design: NSTEMI patients were randomized to complete revascularization during the index procedure (i.e., 1-stage revascularization; n = 264)

Becker RC, et al. Lancet 2009;373:919-28

Invasive versus conservative treatment in unstable coronary syndromes

Peter K. Smith, MD The Journal of Thoracic and Cardiovascular Surgery

J. Trevor Posenau, MD, Daniel M. Wojdyla, MS, Linda K

Effect of PCI on 1-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval (bars);

% Heparin + GPI IIb/IIIa Bivalirudin +

FOURIER Trial design: Patients with established cardiovascular disease on statin therapy were randomized to evolocumab 140 mg subcutaneous every 2 weeks.

Avoiding Cardiovascular Events through COMbination Therapy in Patients LIving with Systolic Hypertension The First Outcomes Trial of Initial Therapy With.

Q.A. Truong et al. Circ Cardiovasc Qual Outcomes 2011;4:

Early and long-term outcomes of coronary artery bypass grafting in patients with acute coronary syndrome versus stable angina pectoris Toshihiro Fukui,

Kaplan-Meier curves: revascularisation rate (PCI or CABG) was significantly higher (p

Potential mechanisms whereby statins may reduce the risk of stroke

Kaplan–Meier estimates of the incidence of first heart failure hospitalization during follow-up according to the statin category among patients with type.

Enrollment and Outcomes

Kaplan-Meier estimate of mortality in 1798 propensity score matched pairs with a propensity score >0.5 for the whole observational period. Kaplan-Meier.

Expanding the Recognition and Assessment of Bleeding Events Associated With Antiplatelet Therapy in Primary Care Marc Cohen, MD Mayo Clinic Proceedings

Flow diagram for exclusions of trials identified RCT indicates randomized controlled trial Hulten E, et al. Arch Intern Med 2006;166:

Flow Diagram of the Trial Selection Process

Baseline Characteristics of the Patients and Use of Concomitant Medications – Part I Kaare Harald Bønaa, et al. N Engl J Med 2006;354:

Baseline Patients with coronary artery disease (CAD) and high (n=98) versus normal (n=1512) high-density lipoprotein (HDL) levels Doreen DeFaria Yeh, et.

Baseline Demographic Characteristics of Adults With Diagnosed Heart Failure and Eligible to Receive Lipid-Lowering Therapy Alan S. Go, et al.

Collet JP, et al. Lancet 2009;373:309-17

SOLID-TIMI 52 Trial design: Participants within 30 days of an acute coronary syndrome (ACS) were randomized to darapladib 160 mg daily (n = 6,504) versus.

Kaplan-Meier curves showing the time in months to the first inappropriate shock from the start of remote monitoring in primary and secondary prevention.

Baseline Characteristics of the Patients – Part I

Cox regression of proportion mortality in the first 8 years for patients with three-vessel disease with a significant difference between the treatment.

Flow diagram of Coronary Artery Bypass Graft-Acute Coronary Syndrome (CABG-ACS) trial. Flow diagram of Coronary Artery Bypass Graft-Acute Coronary Syndrome.

Change in 6 min walk distance from baseline to each follow-up time for subjects randomised to CABG and to medical therapy alone. The median change and.

Baseline Characteristics of the Patients - Part I

Glenn N. Levine et al. JACC 2011;58:e44-e122

Trends in Patient Characteristics and Outcomes of Coronary Artery Bypass Grafting in the 2000 to 2012 Medicare Population Christian McNeely, MD, Stephen.

Baseline Clinical Characteristics of All Patients and Patients Grouped by Statin Therapy - Part I H. Fukuta et al. Circulation 2005;112:

Baseline demographics and clinical characteristics of 3,956 rosuvastatin-treated patients Donald G. Vidt, et al. Am J Cardiol 2006;97:1602–1606.

The benefit of evolocumab treatment is consistent regardless of inflammation level HR %CI ARR 1.6% 1.8%

Davide Capodanno et al. JCIN 2009;2:

Summary of STICH trial patients included in the analysis of 6 min walk distance. Reasons for non-inclusion at each follow-up time are given. CABG, coronary.

Effect of PCI on 3 to 5-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval.

Demographic Characteristics of Patients Treated With Statins Versus Those Not Treated With Statins Goldberger JJ, et al. J Am Coll Cardiol 2006;48:

Kaplan-Meier estimate of mortality in the two treatment strategies with significant difference between the two groups (log-rank test

Change in 6 min walk distance at 12 months in subgroups defined by baseline characteristics. The mean (95% CI) for the difference between CABG and medical.

Kaplan-Meier curve of the primary outcome in patients prescribed ACE inhibitor (ACEI) and angiotensin receptor blocker (ARB). Kaplan-Meier curve of the.

Proposed future revascularisation strategy in patients with ESRD based on our current results and previous guideline recommendations. Proposed future revascularisation.

Presentation transcript:

Baseline characteristics of study population Brilakis ES et al. Am J Cardiol 2008;102:552-8

Biomarkers at baseline and at four months from study enrollment in different treatment groups Brilakis ES et al. Am J Cardiol 2008;102:552-8

Outcomes in patients with and without previous coronary artery bypass grafting Brilakis ES et al. Am J Cardiol 2008;102:552-8

Outcomes with intensive versus moderate statin therapy in patients with and without previous coronary artery bypass grafting in the PROVE IT-TIMI 22 and A to Z trials Brilakis ES et al. Am J Cardiol 2008;102:552-8

Kaplan-Meier estimate of the incidence of the PROVE IT-TIMI 22 primary end point Kaplan-Meier estimate of the incidence of the PROVE IT-TIMI 22 primary end point (death/MI, revascularization 30 days from enrollment, unstable angina, and stroke) and the A to Z primary end point (cardiovascular death/MI/stroke/readmission for ACS) in patients with previous CABG and moderate (green line) or intensive (blue line) statin therapy and those without previous CABG and moderate (orange line) or intensive (purple line) statin therapy. Brilakis ES et al. Am J Cardiol 2008;102:552-8